One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market
The biotech company is awaiting approval on a second drug to drive up revenue as it firms its foothold in a competitive landscape Key Takeaways: Boan Biotechnology sells only one…
RELATED ARTICLES
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
BeiGene’s aggressive expansion brings revenue jolt
BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter